SOGUG-TRIDA研究采用Darolutamida-Docetaxel-TDA三联疗法治疗mHSPC，证实了其在真实世界人群中的价值；该人群的特征比ARASENS研究人群更差。未达到深度PSA应答（>0,2ng/ml）被证实为一项不利终点 #ESMO2026 @sogug1
24 浏览 · 2 赞 · 0 转发 · 0 回复
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：Ricardo Sánchez-E · x.com